What ChondroFiller injection offers when cartilage behind the kneecap is damaged

An MRI report showing cartilage damage behind the kneecap raises an obvious question: does this need surgery? For suitable patients with focal defects in the patellofemoral compartment, ChondroFiller injection offers a non-surgical answer — a 30–45 minute outpatient appointment under ultrasound guidance, with no incision, no general anaesthetic, and no wait for an operating theatre.

The patellofemoral joint is formed by two cartilage-bearing surfaces: the underside of the patella and the femoral trochlear groove it tracks across. Both fall within ChondroFiller's CE-marked Class III indication for focal articular cartilage damage in the knee, across the full ICRS spectrum from early-grade softening to full-thickness lesions.

ChondroFiller injection is not a lubricant. Hyaluronic acid injections coat and cushion the joint temporarily and are cleared within weeks; they do not provide a structural scaffold. ChondroFiller is a purified Type I collagen that self-gels inside the joint within minutes and acts as a biological matrix, recruiting the body's own progenitor cells to progressively rebuild the damaged surface over several months. That biological distinction also separates it from surgery-based repair options such as MACI or OATS, which require theatre time and, in some cases, a two-stage procedure.

Whether this pathway is appropriate depends on individual anatomy and history — a clinical assessment and current MRI are needed to establish that before any treatment decision is made.

Why patellofemoral cartilage rarely heals on its own

Articular cartilage contains no blood vessels and no nerve fibres — a structural fact with a significant clinical consequence. When a focal defect develops, there is no vascular pathway to deliver the repair cells and growth factors that close wounds elsewhere in the body. Left without intervention, the lesion does not stabilise; it gradually widens and deepens.

The patellofemoral compartment is exposed to this problem in a concentrated way. Three mechanisms account for most focal chondral damage here: patellar maltracking, where the kneecap follows an abnormal path through the trochlear groove and creates uneven load distribution across a small contact area; acute patellar dislocation, which can shear cartilage from either surface on relocation; and cumulative overuse from repeated high-load flexion — stair climbing, squatting, or prolonged kneeling — applied to cartilage that has limited capacity to remodel.

Addressing a smaller, shallower defect is consistently more straightforward than managing one that has expanded to reach subchondral bone, and it preserves a broader range of treatment options. That is the practical argument for timely assessment: the biology of the joint does not pause, and the window during which less invasive approaches remain viable is not indefinite.

How the collagen scaffold works inside the joint

ChondroFiller is a two-component Type I collagen liquid that arrives at the clinic as a sterile solution. Once injected into the joint under ultrasound guidance, it meets the knee's neutral pH and polymerises within 3–5 minutes into a stable hydrogel — a soft, three-dimensional matrix that adheres to the cartilage surface and fills the lesion flush with the surrounding tissue.

That matrix is what clinicians mean by a "scaffold." It does not work by lubricating the joint or cushioning it chemically; it works by acting as a chemotactic signal — a structural invitation that draws the patient's own progenitor cells inward from the surrounding synovium and subchondral bone. Those cells migrate into the scaffold, settle, and begin differentiating into chondrocyte-like cells capable of depositing new collagen and proteoglycans: the building blocks of cartilage matrix. This progressive rebuilding — matrix-induced chondrogenesis — unfolds over approximately 6–12 months.

The entire process is acellular. No cartilage biopsy is taken, and no cells are cultured in a laboratory before treatment. Cell-based procedures such as MACI or ACI require both steps — a harvest stage and a separate implantation — which is why they involve theatre time and typically two operations. ChondroFiller injection requires neither, and the biological mechanism of repair is the same whether the scaffold reaches the defect by ultrasound-guided outpatient injection or by arthroscopic placement in theatre.

Precise placement matters: ultrasound guidance allows the injecting clinician to fill the defect accurately without overfilling it. Ex vivo data confirm that flush application avoids fibrous tissue formation, whereas overfilling alters the repair environment.

Who is suitable for the ChondroFiller injection pathway

Suitability for the ChondroFiller injection pathway is shaped less by what a patient has than by what they do not have. The three core prerequisites — MRI-confirmed damage, a mechanically sound knee, and prior conservative care — have been outlined above; what follows concerns the boundary cases where injection alone is insufficient or falls outside scope entirely.

Patellar instability must be corrected first

Where recurrent patellar dislocation or significant malalignment is the underlying driver of cartilage damage, placing a collagen scaffold into a joint that continues to maltrack provides little durable benefit. Tibial tuberosity osteotomy (TTO) or MPFL reconstruction to stabilise the patella may need to be completed first, or performed concurrently alongside any cartilage work.

Significant subchondral bone involvement changes the equation

When a lesion extends deep enough to produce intralesional osteophytes or subchondral cysts, a scaffold applied above the surface cannot address what lies beneath it. Osteochondral procedures — such as autograft transfer (OATS) or fresh osteochondral allograft — may be more appropriate for those cases.

End-stage diffuse osteoarthritis sits outside scope

The injection pathway targets contained focal defects, not joint surfaces affected by widespread degeneration. When the patellofemoral compartment has deteriorated diffusely, patellofemoral arthroplasty or total knee replacement becomes the more relevant conversation.

For defects too complex for injection alone yet short of requiring arthroplasty, a more intensive option exists: a keyhole procedure combining ChondroFiller with mesenchymal stem cell co-delivery — the Liquid Cartilage™ pathway — serves cases where the injection route is insufficient but joint replacement remains premature. A consultant assessment determines which pathway applies.

The outpatient appointment and what to expect during recovery

Arriving at the clinic, the patient sits or lies on a treatment couch while the injecting clinician uses real-time ultrasound to guide the needle precisely to the defect site. The ultrasound view is what allows flush placement — filling the lesion accurately without overfilling it, which, as the previous section established, determines whether the repair environment favours hyaline-like matrix or fibrous tissue. Intravenous antibiotic cover is given as a standard precaution.

Once placed, the collagen liquid begins gelling within 3–5 minutes. The initial hydrogel is soft and not yet mechanically stable under full load, which is the clinical reason — not routine caution — behind post-injection activity restrictions. A biomechanical study confirmed that the gel does not provide protective load-sharing benefit during the early polymerisation phase, so full weight-bearing is reintroduced gradually rather than immediately. Most patients return to light daily activities within days; impact loading follows once the scaffold has firmed and cellular in-migration is under way.

Functional improvement emerges over 3–12 months, reflecting how long progenitor cell recruitment, differentiation, and matrix deposition actually take. In the published knee cohort, Lysholm and IKDC scores improved significantly at 3, 6, and 12 months, with the largest gains evident by 6 months. Follow-up MRI — scored using the MOCART system, which grades cartilage fill, surface integrity, and integration with surrounding native tissue — can track scaffold incorporation across that window without requiring any further procedure.

What the clinical evidence shows — and where gaps remain

The two most cited datasets point in a consistent direction. A 17-patient knee cohort reported statistically significant Lysholm and IKDC score improvements at 3, 6, and 12 months following ChondroFiller treatment; a separate randomised multicentre trial comparing ChondroFiller liquid with microfracture found significant IKDC gains at 3 and 6 months with no adverse events recorded in the ChondroFiller group. Across published series, IKDC scores improve by approximately 30 points, MOCART scaffold-integration scores range between 70 and 87, and the reported complaint rate sits at approximately 0.06%. Ex vivo explant work — covered in the mechanism section above — independently confirms that cellular recruitment and matrix deposition occur within the scaffold in the timeframe the clinical scores reflect, without restating that finding here.

One gap requires plain statement: no published randomised trial has isolated outcomes specifically for patellofemoral defects treated by injection. Applicability to this compartment rests on the CE indication, which covers focal articular cartilage damage across the knee joint including the patellofemoral surfaces, and on the broader knee dataset that supports the biological rationale — though patellofemoral-specific trial evidence has not yet been published. Long-term outcomes beyond five years in this compartment are similarly absent from the literature.

ChondroFiller holds CE Class III status in Europe; it does not carry FDA approval in the United States.

1. [1] Offloading patellofemoral chondral defects requires tailored tibial tuberosity osteotomy procedures. (2024). https://doi.org/10.1016/j.arthro.2024.10.012 https://doi.org/10.1016/j.arthro.2024.10.012